The therapy received Health Canada’s approval to manage heavy menstrual bleeding associated with uterine fibroids. Credit: Chinnapong/Shutterstock.com.

Health Canada has granted a notice of compliance (NOC) to Sumitomo Pharma Canada and Pfizer Canada’s MYFEMBREE (relugolix, estradiol and norethindrone acetate tablets).

The combination therapy, which includes relugolix 40mg, estradiol 1mg and norethindrone acetate 0.5mg, is intended for the management of moderate to severe pain associated with endometriosis in pre-menopausal women.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

In September 2023 it also received approval from Health Canada to manage heavy menstrual bleeding associated with uterine fibroids.

The therapy is recommended for once daily oral dosage.

The approval is based on Phase III studies including LIBERTY 1 and LIBERTY 2 for uterine fibroids, as well as the SPIRIT 1 and SPIRIT 2 clinical trials for endometriosis.

See Also:

Sumitomo Pharma Canada general manager Lisa Mullett stated: “Health Canada’s approval of MYFEMBREE across the uterine fibroid and endometriosis indications marks a significant milestone in our commitment to women’s health.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“These are multi-faceted and complex chronic conditions, and we are proud to make new treatment options available to women in Canada.”

With this approval, Pfizer Canada in partnership with Sumitomo Pharma plans to bring MYFEMBREE to Canadians as quickly as possible.

Both companies are assessing the timeline of availability for MYFEMBREE.

Pfizer Canada primary care portfolio lead Andréa Mueller stated: “MYFEMBREE’s approval is a testament to the shared commitment between our two companies to support women’s health.

“We are proud to help women manage their health at all stages of their lives.”